{
    "id": 30219,
    "fullName": "FGFR2 V563L",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 V563L (corresponds to V562L in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V563L is predicted to confer a gain of function to the Fgfr2 protein as indicated by increased Fgfr2 kinase activity in cell culture, and has been shown to be associated with secondary resistance to FGFR inhibitors (PMID: 25169980, PMID: 31109923).",
            "references": [
                {
                    "id": 15207,
                    "pubMedId": 31109923,
                    "title": "TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31109923"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4388,
                    "pubMedId": 25169980,
                    "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25169980"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "V563L",
    "createDate": "05/30/2019",
    "updateDate": "05/30/2019",
    "referenceTranscriptCoordinates": {
        "id": 179658,
        "transcript": "NM_001144913",
        "gDna": "chr10:g.121496711C>G",
        "cDna": "c.1687G>C",
        "protein": "p.V563L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17143,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion with FGFR2 V565F, K660M E566A, N550H, and N550K mutations, responded to TAS-120 for 7.2 months before progressing due to an acquired FGFR2 V563L mutation, detected in cell-free DNA and tumor biopsy (PMID: 31109923; NCT02052778).",
            "molecularProfile": {
                "id": 32355,
                "profileName": "FGFR2 - ZMYM4 FGFR2 V563L"
            },
            "therapy": {
                "id": 1053,
                "therapyName": "Futibatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15207,
                    "pubMedId": 31109923,
                    "title": "TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31109923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32354,
            "profileName": "FGFR2 V563L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32355,
            "profileName": "FGFR2 - ZMYM4 FGFR2 V563L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 179657,
            "transcript": "XM_006717711",
            "gDna": "chr10:g.121488083C>G",
            "cDna": "c.1687G>C",
            "protein": "p.V563L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 179655,
            "transcript": "NM_022970",
            "gDna": "chr10:g.121496711C>G",
            "cDna": "c.1687G>C",
            "protein": "p.V563L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 179654,
            "transcript": "NM_001144917",
            "gDna": "chr10:g.121487376C>G",
            "cDna": "c.1687G>C",
            "protein": "p.V563L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 179656,
            "transcript": "XM_017015922",
            "gDna": "chr10:g.121488077C>G",
            "cDna": "c.1687G>C",
            "protein": "p.V563L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 179658,
            "transcript": "NM_001144913",
            "gDna": "chr10:g.121496711C>G",
            "cDna": "c.1687G>C",
            "protein": "p.V563L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}